Inclusion criteria: The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population Patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs) will be eligible for enrollment.
Sponsor/Collaborator: Lantern Pharma Inc
Contact and Locations:
https://www.harmonictrial.com/
Name: Ernest Kitt
Phone Number: 972-277-1136
Email: ekitt@lanternpharma.com
Mechanism of action: LP-300, works together with chemotherapy by interacting in the TK gene pathways, interrupting their activity to slow or prevent tumor growth and spread.
Phases: Phase 2
NCT Number: NCT05456256
Status: Recruiting
